NASDAQ:DBVT DBV Technologies (DBVT) Stock Price, News & Analysis $0.89 +0.02 (+2.30%) (As of 08/29/2024 ET) Add Compare Share Share Today's Range$0.89▼$0.9150-Day Range$0.75▼$1.0352-Week Range$0.50▼$3.70Volume6,465 shsAverage Volume50,191 shsMarket Capitalization$85.78 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get DBV Technologies alerts: Email Address DBV Technologies MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside349.9% Upside$4.00 Price TargetShort InterestHealthy0.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.24Based on 5 Articles This WeekInsider TradingSelling Shares$1,749 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.22) to ($0.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.96 out of 5 starsMedical Sector387th out of 940 stocksBiological Products, Except Diagnostic Industry54th out of 143 stocks 3.2 Analyst's Opinion Consensus RatingDBV Technologies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageDBV Technologies has only been the subject of 2 research reports in the past 90 days.Read more about DBV Technologies' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.31% of the float of DBV Technologies has been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DBV Technologies has recently decreased by 4.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBVT. Previous Next 3.5 News and Social Media Coverage News SentimentDBV Technologies has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for DBV Technologies this week, compared to 1 article on an average week.Search Interest2 people have searched for DBVT on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,749.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of DBV Technologies is held by insiders.Percentage Held by Institutions71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DBV Technologies' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($1.22) to ($0.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about DBV Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchPresident Kamala’s first act?The Fix Is In for 2024 If you've watched everything unfold over the past few weeks and wondered, "What in the world could be next?"... You need to watch Dan Ferris' new presentation right away. As you'll see, the Fix is in for 2024... and it threatens to plunge America into an economic nightmare unlike anything we've seen in half a century. It doesn't matter who the Dems pick as their nominee – this is already in motion.Full details here. About DBV Technologies Stock (NASDAQ:DBVT)DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Read More DBVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DBVT Stock News HeadlinesAugust 28 at 6:10 AM | americanbankingnews.comStockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)July 31, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Announces Filing of 2024 Half-Year Report ? Conditions for Accessing or Consulting the ReportAugust 29, 2024 | Stansberry Research (Ad)President Kamala’s first act?The Fix Is In for 2024 If you've watched everything unfold over the past few weeks and wondered, "What in the world could be next?"... You need to watch Dan Ferris' new presentation right away. As you'll see, the Fix is in for 2024... and it threatens to plunge America into an economic nightmare unlike anything we've seen in half a century. It doesn't matter who the Dems pick as their nominee – this is already in motion.July 30, 2024 | globenewswire.comDBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the ReportJuly 30, 2024 | globenewswire.comDBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial ResultsJuly 29, 2024 | globenewswire.comDBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024July 20, 2024 | nz.finance.yahoo.comDBV Technologies SA (DBV0.SG)July 8, 2024 | globenewswire.comHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFAugust 29, 2024 | Stansberry Research (Ad)President Kamala’s first act?The Fix Is In for 2024 If you've watched everything unfold over the past few weeks and wondered, "What in the world could be next?"... You need to watch Dan Ferris' new presentation right away. As you'll see, the Fix is in for 2024... and it threatens to plunge America into an economic nightmare unlike anything we've seen in half a century. It doesn't matter who the Dems pick as their nominee – this is already in motion.June 5, 2024 | globenewswire.comDBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 31, 2024 | globenewswire.comDBV Technologies Announces Plan to Implement ADS Ratio ChangeMay 30, 2024 | globenewswire.comDBV Technologies to Participate in Upcoming EAACI 2024 CongressMay 17, 2024 | marketwatch.comDBV Technologies Plans to Change ADS RatioMay 17, 2024 | msn.comDBV Technologies to implement ADS ratio changeMay 17, 2024 | globenewswire.comDBV Technologies Announces Plan to Implement ADS Ratio ChangeMay 16, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies Announces Results of its 2024 Combined General MeetingMay 16, 2024 | globenewswire.comDBV Technologies Announces Results of its 2024 Combined General MeetingMay 9, 2024 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies to Participate in Upcoming Investor ConferencesSee More Headlines Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today8/29/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside+339.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,730,000.00 Net Margins-638.21% Pretax Margin-638.16% Return on Equity-74.41% Return on Assets-55.84% Debt Debt-to-Equity RatioN/A Current Ratio3.29 Quick Ratio4.51 Sales & Book Value Annual Sales$15.73 million Price / Sales5.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book1.11Miscellaneous Outstanding Shares96,493,000Free Float94,660,000Market Cap$87.81 million OptionableOptionable Beta0.68 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel Tassé (Age 64)CEO & Director Comp: $1.21MDr. Pharis Mohideen (Age 59)Chief Medical Officer Comp: $725.12kMs. Virginie Simone Jeanine Verrechia Boucinha M.B.A. (Age 55)CFO & Principal Accounting Officer Dr. Kevin P. Malobisky M.S.Ph.D., R.A.C., Chief Operations OfficerMs. Michele F. RobertsonChief Legal OfficerMs. Caroline Daniere (Age 49)Chief Human Resources Officer & Chief of Staff Dr. Wence AgbotounouChief Clinical Trial Officer & Senior VPMr. Edward P. Jordan M.B.A. (Age 56)Senior Vice President of Commercial Operations North America Alan KerrSenior VP & Head of Global Regulatory AffairsMr. Pascal WotlingChief External Manufacturing & Supply Chain OfficerMore ExecutivesKey CompetitorsCorMedixNASDAQ:CRMDInozyme PharmaNASDAQ:INZYFoghorn TherapeuticsNASDAQ:FHTXNeoleukin TherapeuticsNASDAQ:NLTXAurora CannabisNASDAQ:ACBView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 1,556,250 shares on 8/19/2024Ownership: 1.613%Pharis MohideenSold 1,785 sharesTotal: $1,749.30 ($0.98/share)Pharis MohideenSold 330 sharesTotal: $897.60 ($2.72/share)Pharis MohideenSold 191 sharesTotal: $527.16 ($2.76/share)Adora NduBought 912 shares on 2/6/2024Total: $1,623.36 ($1.78/share)View All Insider TransactionsView All Institutional Transactions DBVT Stock Analysis - Frequently Asked Questions How have DBVT shares performed this year? DBV Technologies' stock was trading at $1.9056 at the beginning of 2024. Since then, DBVT stock has decreased by 53.3% and is now trading at $0.8890. View the best growth stocks for 2024 here. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) issued its earnings results on Tuesday, July, 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.08. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.42 million. DBV Technologies had a negative trailing twelve-month return on equity of 74.41% and a negative net margin of 638.21%. When did DBV Technologies' stock split? DBV Technologies shares reverse split before market open on Monday, June 3rd 2024. The 1-2 reverse split was announced on Monday, June 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. Who are DBV Technologies' major shareholders? Top institutional investors of DBV Technologies include Point72 Asset Management L.P. (1.61%). Insiders that own company stock include Pharis Mohideen, Timothy E Morris and Adora Ndu. View institutional ownership trends. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX) and AbbVie (ABBV). This page (NASDAQ:DBVT) was last updated on 8/29/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressHow likely is a Trump victory? Polymarket (the world's largest prediction market) gives Trump a 63% chance ...Colonial Metals | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredPresident Kamala’s first act?The Fix Is In for 2024 If you've watched everything unfold over the past few weeks and wondered, "What in t...Stansberry Research | SponsoredIntroducing The AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBuried under the blight of America’s most dangerous cityIn this video, I’ll show you how to get on the right side of this wealth transfer before it kicks into overdri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
